In a roundabout development scientists say that colon cancer , a disease triggered by deactivated hormones , could be treated by hormone therapy.
A study in this month's issue of the journal Gastroenterology, reveals that GCC, a protein receptor on the surface of intestinal epithelial cells for two hormones, guanylin and uroguanylin, can indeed subdue tumour formation. These hormones are the ones that regulate the growth of the intestinal cells.
New Study Finds That Hormone Deficiency Could Lead to Colon Cancer
Researchers have found new evidence suggesting that colon cancer is actually a disease of missing hormones.
Advertisement
In early stages of the disease, these growth-controlling hormones are deactivated. This disrupts GCC's activity and contributes to tumour formation, says lead author Scott Waldman of Jefferson Medical College.
In conclusion, the study findings "converts colon cancer from a genetic disease, which is the way we've all thought about it, to a disease of hormone insufficiency," says Waldman. "It's a completely different way of thinking about the disease", he points out.
![Routine Colon Examination On US President Reveals No Cancerous Polyps]( "Routine Colon Examination On US President Reveals No Cancerous Polyps")
The White House revealed that there were no cancerous cells in five polyps removed from President Bush during a recent routine colon exam .
Using two separate mouse models that mimic the development of colon cancer in people, researchers showed that GCC signaling blocks cancerous tumours from forming in the colon. When GCC was removed from the mice and a carcinogen introduced, researchers found tumours larger and in greater number in both the colon and intestines.
The same situation occurred in mice that carried a mutation of the APC gene, which causes the growth of colon polyps that lead to colon cancer. Putting them together, exposure to a carcinogen or mutations in APC, along with the loss of GCC signaling is "a recipe for colon cancer," Waldman says.
Riding on the wave of this discovery, researchers would like to further show that by treating patients with hormone replacement therapy, intestinal cancer formation can either be prevented or treated.
Source: Medindia
ANN/B
Routine Colon Examination On US President Reveals No Cancerous Polyps
The White House revealed that there were no cancerous cells in five polyps removed from President Bush during a recent routine colon exam .
Advertisement
Using two separate mouse models that mimic the development of colon cancer in people, researchers showed that GCC signaling blocks cancerous tumours from forming in the colon. When GCC was removed from the mice and a carcinogen introduced, researchers found tumours larger and in greater number in both the colon and intestines.
The same situation occurred in mice that carried a mutation of the APC gene, which causes the growth of colon polyps that lead to colon cancer. Putting them together, exposure to a carcinogen or mutations in APC, along with the loss of GCC signaling is "a recipe for colon cancer," Waldman says.
Riding on the wave of this discovery, researchers would like to further show that by treating patients with hormone replacement therapy, intestinal cancer formation can either be prevented or treated.
Source: Medindia
ANN/B
Genetic Marker That Increases Colon Cancer Risk Discovered
Boffins have discovered a genetic marker that increases a person's risk of colon cancer by 23 percent.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable